{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:16:21Z","timestamp":1776824181161,"version":"3.51.2"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mycobacterium abscessus is an important cause of pulmonary infections, particularly among people with cystic fibrosis. Current treatment options for M. abscessus are suboptimal. Apramycin is a promising alternative aminoglycoside for M. abscessus, in part due to its ability to avoid intrinsic aminoglycoside-modifying enzymes in this pathogen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Define the pharmacodynamic activity of apramycin doses against M. abscessus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Apramycin and amikacin pharmacodynamics were assessed against two amikacin-susceptible M. abscessus subsp. abscessus isolates (ATCC 19977 and NR-44261) using a 14-day hollow fibre infection model (HFIM). Viable bacterial counts were determined during exposure to amikacin (15\u201320\u2005mg\/kg q24h) and 3 fractionated doses of apramycin (15\u2005mg\/kg q12h, 30\u2005mg\/kg q24h, 60\u2005mg\/kg q48h) using pharmacokinetic profiles predicted in epithelial lining fluid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Against ATCC 19977, apramycin activity exceeded that of amikacin, with maximum bacterial reductions between 1.51 and 2.18\u2005log10\u2005cfu\/mL for the different doses. Apramycin 15\u2005mg\/kg q12h displayed slightly better killing compared with the other apramycin dosing regimens between 96 and 144h before regrowth occurred. NR-44261 was not inhibited by amikacin and the activity of apramycin against this isolate was similar between the three doses (\u223c0.5\u2005log10\u2005cfu\/mL reductions). After 14\u2005days of exposure to apramycin monotherapy, ATCC 19977 and NR-44261 became apramycin resistant with MICs of &amp;gt;32\u2005mg\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Apramycin exhibited greater pharmacodynamic activity than amikacin against amikacin-susceptible M. abscessus isolates and may be a promising therapy for this pathogen. However, antibiotic combination strategies to minimize apramycin resistance from emerging may be necessary.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf073","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T10:17:42Z","timestamp":1741861062000},"page":"1309-1314","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacodynamic assessment of apramycin against <i>Mycobacterium abscessus<\/i> in a hollow fibre infection model"],"prefix":"10.1093","volume":"80","author":[{"given":"Nidhi","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Retzky College of Pharmacy, University of Illinois Chicago , 833 South Wood Street, Room 164 (M\/C 886), Chicago, IL 60612 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bikash","family":"Dangi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Retzky College of Pharmacy, University of Illinois Chicago , 833 South Wood Street, Room 164 (M\/C 886), Chicago, IL 60612 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy J","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Retzky College of Pharmacy, University of Illinois Chicago , 833 South Wood Street, Room 164 (M\/C 886), Chicago, IL 60612 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6227-7580","authenticated-orcid":false,"given":"Arnold","family":"Louie","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida , Orlando, FL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunkumar","family":"Karunanidhi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Retzky College of Pharmacy, University of Illinois Chicago , 833 South Wood Street, Room 164 (M\/C 886), Chicago, IL 60612 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke N","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Retzky College of Pharmacy, University of Illinois Chicago , 833 South Wood Street, Room 164 (M\/C 886), Chicago, IL 60612 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-077X","authenticated-orcid":false,"given":"Satoshi","family":"Mitarai","sequence":"additional","affiliation":[{"name":"Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L","family":"Daley","sequence":"additional","affiliation":[{"name":"Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health , Denver, CO ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven N","family":"Hobbie","sequence":"additional","affiliation":[{"name":"Division of Clinical Bacteriology and Mycology, University Hospital Basel , Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-911X","authenticated-orcid":false,"given":"Zackery P","family":"Bulman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Retzky College of Pharmacy, University of Illinois Chicago , 833 South Wood Street, Room 164 (M\/C 886), Chicago, IL 60612 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"2025050205524004400_dkaf073-B1","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","article-title":"Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems","volume":"182","author":"Prevots","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2025050205524004400_dkaf073-B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.thorsurg.2018.09.008","article-title":"Nontuberculous mycobacterial infections in cystic fibrosis","volume":"29","author":"Martiniano","year":"2019","journal-title":"Thorac Surg Clin"},{"key":"2025050205524004400_dkaf073-B3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3201\/eid2203.150828","article-title":"Treatment of Mycobacterium abscessus infection","volume":"22","author":"Novosad","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2025050205524004400_dkaf073-B4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025050205524004400_dkaf073-B5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/cid\/ciq237","article-title":"Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease","volume":"52","author":"Jarand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025050205524004400_dkaf073-B6","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/jac\/dkx125","article-title":"Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes","volume":"72","author":"Rominski","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025050205524004400_dkaf073-B7","doi-asserted-by":"publisher","first-page":"e0151021","DOI":"10.1128\/aac.01510-21","article-title":"Apramycin overcomes the inherent lack of antimicrobial bactericidal activity in Mycobacterium abscessus","volume":"66","author":"Selchow","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205524004400_dkaf073-B8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4103\/ijmy.ijmy_73_18","article-title":"Antimycobacterial activity of veterinary antibiotics (apramycin and framycetin) against Mycobacterium abscessus: implication for patients with cystic fibrosis","volume":"7","author":"Moore","year":"2018","journal-title":"Int J Mycobacteriol"},{"key":"2025050205524004400_dkaf073-B9","doi-asserted-by":"publisher","first-page":"e01347-17","DOI":"10.1128\/AAC.01347-17","article-title":"Mycobacterium abscessus WhiB7 regulates a species-specific repertoire of genes to confer extreme antibiotic resistance","volume":"61","author":"Hurst-Hess","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205524004400_dkaf073-B10","volume-title":"Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes, 3rd Edition. CLSI Document M24","author":"CLSI","year":"2018"},{"key":"2025050205524004400_dkaf073-B11","author":"Minh-Vu"},{"key":"2025050205524004400_dkaf073-B12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/jac\/dkae461","article-title":"In vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution","volume":"80","author":"Nguyen","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025050205524004400_dkaf073-B13","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1128\/AAC.02282-15","article-title":"Amikacin pharmacokinetics\/pharmacodynamics in a novel hollow-fiber Mycobacterium abscessus disease model","volume":"60","author":"Ferro","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205524004400_dkaf073-B14","doi-asserted-by":"publisher","first-page":"e0069221","DOI":"10.1128\/AAC.00692-21","article-title":"Generating genotype-specific aminoglycoside combinations with ceftazidime\/avibactam for KPC-producing Klebsiella pneumoniae","volume":"65","author":"Huang","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205524004400_dkaf073-B15","doi-asserted-by":"publisher","first-page":"e0139323","DOI":"10.1128\/aac.01393-23","article-title":"Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokinetics","volume":"68","author":"Shin","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205524004400_dkaf073-B16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/0885066618754784","article-title":"Evaluation of epithelial lining fluid concentration of amikacin in critically ill patients with ventilator-associated pneumonia","volume":"35","author":"Najmeddin","year":"2020","journal-title":"J Intensive Care Med"},{"key":"2025050205524004400_dkaf073-B17","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1093\/jac\/dkac225","article-title":"Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose","volume":"77","author":"Zhao","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025050205524004400_dkaf073-B18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1378\/chest.128.2.545","article-title":"Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia","volume":"128","author":"Panidis","year":"2005","journal-title":"Chest"},{"key":"2025050205524004400_dkaf073-B19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0009-9236(99)70103-7","article-title":"Tobramycin penetration into epithelial lining fluid of patients with pneumonia","volume":"65","author":"Carcas","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"2025050205524004400_dkaf073-B20","doi-asserted-by":"publisher","first-page":"e0192821","DOI":"10.1128\/Spectrum.01928-21","article-title":"Minimum inhibitory concentrations before and after antibacterial treatment in patients with Mycobacterium abscessus pulmonary disease","volume":"9","author":"Fujiwara","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2025050205524004400_dkaf073-B21","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.1128\/AAC.00990-16","article-title":"Failure of the amikacin, cefoxitin, and clarithromycin combination regimen for treating pulmonary Mycobacterium abscessus infection","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205524004400_dkaf073-B22","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/phar.2193","article-title":"Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing","volume":"38","author":"Bland","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2025050205524004400_dkaf073-B23","doi-asserted-by":"publisher","first-page":"e0322223","DOI":"10.1128\/spectrum.03222-23","article-title":"Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence","volume":"12","author":"Gibson","year":"2024","journal-title":"Microbiol Spectr"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1309\/62398314\/dkaf073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1309\/62398314\/dkaf073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:52:48Z","timestamp":1746179568000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/5\/1309\/8074790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,13]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf073","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,13]]}}}